These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 32011965

  • 1. Medication Adherence, Health Care Utilization, and Costs Among Patients Initiating Oral Oncolytics for Multiple Myeloma or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
    Dashputre AA, Gatwood KS, Gatwood J.
    J Manag Care Spec Pharm; 2020 Feb; 26(2):186-196. PubMed ID: 32011965
    [Abstract] [Full Text] [Related]

  • 2. Impact of oral oncolytic initiation on medication adherence for pre-existing comorbid chronic conditions.
    Dashputre AA, S Gatwood K, Schmidt J, Gatwood J.
    J Oncol Pharm Pract; 2020 Jun; 26(4):835-845. PubMed ID: 31575355
    [Abstract] [Full Text] [Related]

  • 3. Time to Next Treatment, Health Care Resource Utilization, and Costs Associated with Ibrutinib Use Among U.S. Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrospective Analysis.
    Huang Q, Borra S, Li J, Wang L, Shrestha S, Sundaram M, Janjan N.
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1266-1275. PubMed ID: 32880204
    [Abstract] [Full Text] [Related]

  • 4. Assessing the association between medication adherence, as defined in quality measures, and disease-state control, health care utilization, and costs in a retrospective database analysis of Medicare supplemental beneficiaries using statin medications.
    Axon DR, Vaffis S, Chinthammit C, Lott BE, Taylor AM, Pickering M, Black H, Warholak T, Campbell PJ.
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1529-1537. PubMed ID: 33251989
    [Abstract] [Full Text] [Related]

  • 5. Clinical and economic burden of tumor lysis syndrome among patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: A real-world US retrospective study.
    Rogers KA, Lu X, Emond B, Côté-Sergent A, Kinkead F, Lafeuille MH, Lefebvre P, Huang Q.
    J Manag Care Spec Pharm; 2022 Sep; 28(9):1033-1045. PubMed ID: 35816124
    [Abstract] [Full Text] [Related]

  • 6. Costs and health care resource utilization among Medicare beneficiaries diagnosed with chronic lymphocytic leukemia.
    Lee TY, Johnson A, Cooke CE, Yared JA, Summers A, Yang K, Liu S, Tang B, Onukwugha E.
    J Manag Care Spec Pharm; 2024 May; 30(5):430-440. PubMed ID: 38701030
    [Abstract] [Full Text] [Related]

  • 7. Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia.
    Huang Q, Emond B, Lafeuille MH, Gupta D, Lefebvre P, Sundaram M, Mato A.
    Curr Med Res Opin; 2020 Dec; 36(12):2009-2018. PubMed ID: 33044848
    [Abstract] [Full Text] [Related]

  • 8. Tyrosine Kinase Inhibitors and the Relationship With Adherence, Costs, and Health Care Utilization in Commercially Insured Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study.
    Phuar HL, Begley CE, Chan W, Krause TM.
    Am J Clin Oncol; 2020 Jul; 43(7):517-525. PubMed ID: 32304434
    [Abstract] [Full Text] [Related]

  • 9. Real-world Prescription Pattern, Discontinuation and Costs of Ibrutinib-Naïve Patients with Chronic Lymphocytic Leukemia: An Italian Healthcare Administrative Database Analysis.
    Ronconi G, Dondi L, Calabria S, Piccinni C, Pedrini A, Esposito I, Martini N.
    Clin Drug Investig; 2021 Jul; 41(7):595-604. PubMed ID: 34032988
    [Abstract] [Full Text] [Related]

  • 10. Health care resource utilization and costs associated with nonadherence and nonpersistence to antidepressants in major depressive disorder.
    Ta JT, Sullivan SD, Tung A, Oliveri D, Gillard P, Devine B.
    J Manag Care Spec Pharm; 2021 Feb; 27(2):223-239. PubMed ID: 33506730
    [Abstract] [Full Text] [Related]

  • 11. Evaluating the relationship between quality measure adherence definitions and economic outcomes in commercial health plans: a retrospective diabetes cohort study.
    Chinthammit C, Axon DR, Mollon L, Taylor AM, Pickering M, Black H, Warholak T, Campbell PJ.
    J Manag Care Spec Pharm; 2021 Jan; 27(1):64-72. PubMed ID: 33377445
    [Abstract] [Full Text] [Related]

  • 12. Healthcare resource utilization and costs of chronic lymphocytic leukemia/small lymphocytic lymphoma patients who relapse or are refractory to ibrutinib.
    De Nigris E, Yang X, Zanardo E, Lejeune D, Farooqui MZ, Gandra SR, Laliberté F.
    Future Oncol; 2024 Jan; 20(35):2723-2735. PubMed ID: 39373600
    [Abstract] [Full Text] [Related]

  • 13. Real-World Health Plan Data Analysis: Key Trends in Medication Adherence and Overall Costs in Patients with HIV.
    Kangethe A, Polson M, Lord TC, Evangelatos T, Oglesby A.
    J Manag Care Spec Pharm; 2019 Jan; 25(1):88-93. PubMed ID: 30589631
    [Abstract] [Full Text] [Related]

  • 14. Impact of initiating oral anticancer agents for leukemia on adherence to medications for multiple chronic conditions.
    Gatwood J, Dashputre A, Rajpurohit A, Gatwood K, Mackler E, Wallace L, Farris K, Rizvi-Toner A, Farley J.
    J Oncol Pharm Pract; 2024 Mar; 30(2):342-353. PubMed ID: 37113049
    [Abstract] [Full Text] [Related]

  • 15. Treatment utilization patterns of newly initiated oral anticancer agents in a national sample of Medicare beneficiaries.
    Doshi JA, Jahnke J, Raman S, Puckett JT, Brown VT, Ward MA, Li P, Manz CR.
    J Manag Care Spec Pharm; 2021 Oct; 27(10):1457-1468. PubMed ID: 34595957
    [Abstract] [Full Text] [Related]

  • 16. Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency.
    Latremouille-Viau D, Guerin A, Gagnon-Sanschagrin P, Dea K, Cohen BG, Joseph GJ.
    J Manag Care Spec Pharm; 2017 Feb; 23(2):214-224. PubMed ID: 28125373
    [Abstract] [Full Text] [Related]

  • 17. The Association Between Adherence to Insulin Therapy and Health Care Costs for Adults with Type 2 Diabetes: Evidence from a U.S. Retrospective Claims Database.
    Eby EL, Bajpai S, Faries DE, Haynes VS, Lage MJ.
    J Manag Care Spec Pharm; 2020 Sep; 26(9):1081-1089. PubMed ID: 32857656
    [Abstract] [Full Text] [Related]

  • 18. Higher costs and therapeutic factors associated with adherence to NCQA HEDIS antidepressant medication management measures: analysis of administrative claims.
    Robinson RL, Long SR, Chang S, Able S, Baser O, Obenchain RL, Swindle RW.
    J Manag Care Pharm; 2006 Sep; 12(1):43-54. PubMed ID: 16420107
    [Abstract] [Full Text] [Related]

  • 19. Risk Factors, Health Care Resource Utilization, and Costs Associated with Nonadherence to Antiretrovirals in Medicaid-Insured Patients with HIV.
    Dunn K, Lafeuille MH, Jiao X, Romdhani H, Emond B, Woodruff K, Pesa J, Tandon N, Lefebvre P.
    J Manag Care Spec Pharm; 2018 Oct; 24(10):1040-1051. PubMed ID: 29877140
    [Abstract] [Full Text] [Related]

  • 20. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
    Vogelzang NJ, Pal SK, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Meiselbach MK, Perez JR, Agarwal N.
    J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.